ARMATA PHARMACEUTICALS, INC.

(ARMP)
  Bericht
Verzögert Nyse  -  22:00 24.06.2022
3.350 USD    0.00%
23.05.Armata Pharmaceuticals gibt bekannt, dass der erste Patient in einer frühen Studie mit AP-SA02 zur Behandlung von Blutstrominfektionen behandelt wurde
MT
23.05.Armata Pharmaceuticals gibt die Verabreichung des ersten Patienten in der Phase 1b/2a 'diSArm' Studie von AP-SA02 bei Erwachsenen mit Bakteriämie durch Staphylococcus Aureus bekannt
CI
12.05.Armata Pharmaceuticals, Inc. meldet Ergebnis für das erste Quartal zum 31. März 2022
CI
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivate 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-News
Nachrichten in anderen Sprachen über ARMATA PHARMACEUTICALS, INC.
24.05.Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of A..
23.05.Armata Pharmaceuticals Says First Patient Dosed in Early Trial of AP-SA02 to Treat Bloo..
23.05.Armata Pharmaceuticals Announces First Patient Dosed in Phase 1b/2a 'diSArm' Study of A..
12.05.ARMATA PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITI..
12.05.Armata Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March..
01.04.Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $45 Million Pri..
31.03.ARMATA PHARMACEUTICALS : Announces Closing of Second and Final Tranche of $45 Million Priv..
31.03.ARMATA PHARMACEUTICALS, INC. : Unregistered Sale of Equity Securities, Submission of Matte..
31.03.Armata Pharmaceuticals, Inc. announced that it has received $45 million in funding from..
30.03.Armata Pharmaceuticals Files Shelf on Behalf of Certain Selling Stocholders
28.03.ARMATA PHARMACEUTICALS, INC. : Change in Directors or Principal Officers, Financial Statem..
28.03.Armata Pharmaceuticals, Inc. Announces Executive Changes
28.03.Armata Pharmaceuticals, Inc. Announces CFO Changes
18.03.Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2021 Results and Provides..
17.03.ARMATA PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITI..
17.03.Armata Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 3..
17.03.Armata Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended Decem..
17.03.Armata Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt
23.02.Armata Pharmaceuticals Announces Clearance of Investigational New Drug Application to I..
22.02.Armata Pharmaceuticals Gets US FDA Clearance for Non-Cystic Fibrosis Bronchiectasis Tre..
22.02.Armata Pharmaceuticals, Inc. Announces Clearance of Investigational New Drug Applicatio..
18.02.Armata Pharmaceuticals to Participate in Two Upcoming Investor Conferences
11.02.ARMATA PHARMACEUTICALS : Announces $45 Million Investment to Support Advancement of the Co..
11.02.ARMATA PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Unregistered Sa..
10.02.Armata Pharmaceuticals Announces $45 Million Investment to Support Advancement of the C..
09.02.Armata Pharmaceuticals Inc. announced that it expects to receive $45 million in funding..
05.01.ARMATA PHARMACEUTICALS, INC. : Regulation FD Disclosure, Other Events, Financial Statement..
05.01.Armata Pharmaceuticals Provides Update on Pseudomonas Respiratory Programs
2021Armata Cleared by US FDA to Start Trial of Staphylococcus Aureus Bacteremia Treatment; ..
2021Armata Pharmaceuticals Provides Regulatory and Clinical Update Reflecting Sustained Pro..
2021Armata Pharmaceuticals Announces Third Quarter Results and Provides General Corporate U..
2021ARMATA PHARMACEUTICALS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITI..
2021Armata Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Mon..
2021Armata Pharmaceuticals to Present at the 2021 World Antimicrobial Resistance Congress
2021Square foot facility in Los Angeles enables a substantial increase in manufacturing sca..
2021ARMATA PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Other Events, F..
2021Armata Pharmaceuticals Inc. Enters Lease to Build State-Of-The-Art R&D and GMP Manufact..
2021Funds to be used to further advance development of lead candidate AP-PA02, which is bei..
2021ARMATA PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Unregistered Sa..
2021Armata Pharmaceuticals Secures $7 Million Investment From Cystic Fibrosis Foundation, I..
2021Cystic Fibrosis Foundation Makes Equity Investment in Armata Pharmaceuticals
2021Top Premarket Decliners
2021ARMATA PHARMACEUTICALS : to Participate in the H.C. Wainwright 23rd Annual Global Investme..
2021ARMATA PHARMACEUTICALS : Announces Second Quarter Results and Provides General Corporate U..
2021ARMATA PHARMACEUTICALS, INC. : Results of Operations and Financial Condition (form 8-K)
2021ARMATA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND R..
2021Armata Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the S..
2021ARMATA PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)
2021Armata Pharmaceuticals Inc. Appoints Brian Varnum as Member of its Board of Directors
2021ARMATA PHARMACEUTICALS : Announces Chief Executive Officer Transition
2021ARMATA PHARMACEUTICALS : Says CEO Retiring; Successor Named
2021Armata Pharmaceuticals Inc. Announces Executive Changes
2021ARMATA PHARMACEUTICALS : to Present at the Ladenburg Thalmann 2021 Healthcare Conference
2021ARMATA PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders, Other ..
2021ARMATA PHARMACEUTICALS, INC. : Results of Operations and Financial Condition (form 8-K)
2021ARMATA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND R..
2021Armata Pharmaceuticals Inc. Provides Unaudited Consolidated Earnings Results for the Qu..
2021ARMATA PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)
2021ARMATA PHARMACEUTICALS : Announces Fourth Quarter and Full Year 2020 Results and Provides ..
2021ARMATA PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND R..
2021Armata Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 3..
2021ARMATA PHARMACEUTICALS : Announces Closing of Second and Final Tranche of $20 Million Priv..
2021Armata Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt
2021INSIDER TRENDS : 90-Day Buying Trend Extended with Insider Purchase of Armata Pharmaceutic..
2021ARMATA PHARMACEUTICALS, INC. : Unregistered Sale of Equity Securities, Submission of Matte..
2021ARMATA PHARMACEUTICALS : to Present at the Oppenheimer 31st Annual Healthcare Conference
2021INSIDER TRENDS : 90-Day Insider Selling Trend at Armata Pharmaceuticals Slowed with Acquis..
2021ARMATA PHARMACEUTICALS : Announces $20 Million Investment to Support Advancement of the Co..
2021SECTOR UPDATE : Health Care Stocks Ending Near Wednesday Session Lows
2021SECTOR UPDATE : Health Care Stocks Still on Steep Slide
2021ARMATA PHARMACEUTICALS : to Sell $20 Million in Stock, Warrants to Largest Shareholder
2021ARMATA PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Unregistered Sa..
2021ARMATA PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits..
2020ARMATA PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders, Other ..
2020Armata Pharmaceuticals, Inc. Announces Board Changes
1  2  3Weiter
Anstehende Termine für ARMATA PHARMACEUTICALS, INC.